EMBC Embecta Corp.
HealthcareAs of 2026-05-26
Valuation
View DetailsP/E (TTM)
3.76
PEG
0.03
P/B
-0.31
P/S
0.19
EV/EBITDA
4.11
DCF Value
$39.73
FCF Yield
103.9%
Div Yield
18.1%
Margins & Returns
Gross Margin
62.5%
Operating Margin
29.8%
Net Margin
10.7%
ROE
-17.5%
ROA
10.9%
ROIC
25.8%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 null | $221.8M | $-4.1M | $— |
| Q1 null | $261.2M | $44.1M | $— |
| Q4 null | $264.0M | $26.4M | $— |
| FY null | $1.08B | $95.4M | $— |
Analyst Ratings
View AllConsensus
Hold
Target (Consensus)
$5.00
Target (Median)
$5.00
Target Range
$5.00 - $5.00
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
US
Exchange
—
Beta
1.05
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.